Clinical Implications of the Autophagy Core Gene Variations in Advanced Lung Adenocarcinoma Treated with Gefitinib

Authors:

Abstract
EGFR-TKIs show dramatic treatment benefits for advanced lung adenocarcinoma patients with activatingEGFRmutations. Considering the essential role of autophagy in EGFR-TKIs treatments, we hypothesized that genetic variants in autophagy core genes might contribute to outcomes of advanced lung adenocarcinoma treated with gefitinib. We systematically examined 27 potentially functional genetic polymorphisms in 11 autophagy core genes among 108 gefitinib-treated advanced lung adenocarcinoma patients. We found thatATG10rs10036653,ATG12rs26538,ATG16L1rs2241880 andATG16L2rs11235604 were significantly associated with survival of lung adenocarcinoma patients (allP < 0.05). AmongEGFR-mutant patients,ATG5rs688810,ATG5rs510432,ATG7rs8154,ATG10rs10036653,ATG12rs26538,ATG16L1rs2241880 andATG16L2rs11235604 significantly contributed to disease prognosis. We also found thatATG5rs510432,ATG5rs688810,ATG10rs10036653 andATG10rs1864182 were associated with primary or acquired resistance to gefitinib. Functional analyses ofATG10rs10036653 polymorphism suggested thatATG10A allele might increase transcription factor OCT4 binding affinity compared to the T allele in lung cancer cells. Our results indicate that autophagy core genetic variants show potential clinical implications in gefitinib treatment, especially among advanced lung adenocarcinoma patients, highlighting the possibility of patient-tailored decisions during EGFR-TKIs based on both germline and somatic variation detection.